Stifel cuts Leidos stock price target on health segment concerns
Stifel cut its Leidos Holdings (NYSE:LDOS) price target to $142 from $193 and kept a Hold rating, citing concerns about the company’s Health segment despite strong Q2 results. Leidos reported adjusted EPS of $3.26 vs $2.91 expected and revenue of $4.56B vs $4.44B, raised full-year 2026 guidance, and saw organic revenue growth of 4% YoY.
How this was made
The 30-second read
Why it matters
The key trading takeaway is the sell-side PT reset tied to margin and execution concerns in the highest-margin Health segment, which can pressure the stock even after a beat-and-raise.
Market read
A PT cut with a specific segment-level thesis can drive near-term positioning changes, especially when the market is already digesting a beat-and-raise.
What to watch
The article notes raised full-year guidance and improved award environment for Defense (book-to-bill 2.2x), which could reduce the market’s sensitivity to Health margin headwinds if execution stabilizes.
Background
Leidos reported Q2 2026 results that beat estimates and raised full-year guidance, but Stifel still lowered its PT due to Health segment risk signals.
Ticker impact
Stifel cut Leidos (LDOS) price target to $142 from $193, citing health-segment concerns despite Q2 results and raised full-year guidance.
Near term, downside bias versus peers is likely as traders weigh the PT reduction against the beat-and-raise.
The article’s actionable new item is the PT reduction with a specific thesis (Health segment cautionary indicators like incentive-fee suspension and in-sourcing DHA Genesis work). It does not provide new financial datapoints beyond what is already framed as Q2 beat and guidance raise, so impact is likely moderate rather than a full repricing catalyst.
Market effects
Highlights how defense contractors’ segment mix and margin structure can dominate even when consolidated results beat.
Limited, primarily affects US defense-services sentiment.
Low, no cross-border deal or regulatory action described.
Counterpoint
The Health-segment issues may be transitional (contract fee suspension and in-sourcing efforts) and could be offset by continued strength in Defense book-to-bill and cash flow.
Key entities
- companyLeidos Holdings
Defense contractor whose Health segment is flagged by Stifel as a margin risk, prompting a PT cut.
- analyst_firmStifel
Lowered LDOS price target to $142 from $193 while keeping a Hold rating.
